Ygalo is a peptidase potentiated alkylator, a type of cytotoxic drug. Ygalo differs from current cytotoxics through its unique ability to achieve higher concentrations of cancer killing molecules in cancer cells without a corresponding increase in damage to the patient’s bone marrow. Pre-clinical studies also show that Ygalo kills on average 50 times more cancer cells than similar classes of treatment.
Ygalo is intended to be the first choice for the treatment of patients with late-stage relapsed and refractory multiple myeloma. Multiple myeloma is a haematological cancer with no cure and a median survival period of approximately 5 years from diagnosis. Patients in the late stages of multiple myeloma suffer from symptoms including skeletal pain, bone fractures and infections associated with a weakened immune system as well as from the side effects of the treatments available today.
Comparing clinical data between Ygalo and the current standard of care in late-stage multiple myeloma indicates that treatment with Ygalo increases overall survival, progression free survival and the number of patients with significant tumour burden reduction as well as being better tolerated by patients.
Ygalo will shortly commence a pivotal Phase 3 clinical study approved under the US Food and Drug Administration’s Special Protocol Assessment where it will be compared directly against the current standard of care in patients suffering late-stage multiple myeloma.
As a rare condition, multiple myeloma is classified as an orphan disease in the US and Europe and Ygalo has been granted orphan drug designation by the relevant authorities in both these jurisdictions.